INGR earnings analysis
What we found in INGR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ingredion delivered $1.850 billion of second-quarter revenue and $2.82 of adjusted EPS, both above consensus, but reported EPS was only $1.78 and operating income declined to $188 million, reflecting acquisition, impairment and restructuring items. Management reaffirmed FY2026 adjusted EPS guidance of $10.30-$10.90, while projecting low-single-digit Q3 sales growth and a mid-single-digit operating-income decline. The pending Tate & Lyle transaction adds significant execution, foreign-exchange and leverage risks, with potential post-close debt of approximately $6.0 billion versus $1.8 billion currently.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and adjusted EPS beat estimates
- Second-quarter revenue was $1.850 billion, approximately 1.1% above the $1.829 billion consensus estimate, while adjusted EPS was $2.82 versus the $2.78 estimate.
- FY2026 outlook reaffirmed
- Management reaffirmed FY2026 adjusted EPS of $10.30-$10.90 and reported EPS of $9.15-$9.75, indicating no change to the previously amended outlook.
- Acquisition FX exposure hedged
- The company established sterling hedges covering £2,793 million of exposure related to the pending Tate & Lyle acquisition; a 10% decline in the U.S. dollar versus sterling would produce an estimated $265 million derivative gain, excluding the $47 million year-to-date loss already recorded in financing costs.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial post-acquisition leverage
- The pending Tate & Lyle acquisition is expected to require up to approximately $4.2 billion of additional indebtedness, potentially bringing consolidated debt to approximately $6.0 billion versus $1.8 billion as of June 30, 2026.
- Tate & Lyle closing risk
- The acquisition remains subject to competition and antitrust clearances in the United States, United Kingdom, European Union, China and other countries; failure to complete the transaction could adversely affect the business, financial results and stock price.
- Derivative settlement exposure
- The company sold a put contract covering £2,793 million of sterling exposure. If sterling falls below the strike price, Ingredion could be required to settle the contract at an unfavorable exchange rate, resulting in material losses and cash payments.
- Earnings volatility from FX derivatives
- The acquisition derivatives are not designated as cash flow hedges, so fair-value changes flow through earnings; the company recorded a $47 million year-to-date loss in financing costs through June 30, 2026.
- Future debt covenant pressure
- After closing, credit agreements will require compliance with maximum consolidated leverage and minimum consolidated interest-coverage ratios; failure to comply could trigger default and acceleration of debt, although the filing does not provide the covenant thresholds.
- Q3 operating income decline
- The company expects Q3 net sales to increase low single digits, but reported and adjusted operating income are expected to decline mid-single digits, signaling near-term profit pressure despite modest sales growth.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.78
What they said about what is next.
FY2026 adjusted EPS outlook was reaffirmed at $10.30-$10.90, with reported EPS expected at $9.15-$9.75. Full-year net sales are expected to be flat to up low-single digits; Q3 net sales are expected to rise low single digits, while reported and adjusted operating income are expected to decline mid-single digits.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Ingredion Incorporated reported Q1 2026 revenues of $1.79 billion and EPS of $2.34, slightly exceeding revenue estimates but falling short on EPS expectations. Compared to Q1 2025, net sales decreased by 1%, while net…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INGR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever